IMIM (Institut Hospital del Mar d'Investigacions Mèdiques)
Barcelona, 08003, Spain
NCT Number: NCT03624556
To evaluate safety and tolerability of epigallocatechin gallate (EGCG) in children from 6 to 12 years old with Intellectual Developmental Disorders (IDD) (Down syndrome or Fragile X syndrome).
Looking for future studies?
Notify Me6 year–12 year
All sexes
Interventional
Not applicable
Barcelona, 08003, Spain
This project first objective is to evaluate the safety and tolerability of the EGCG molecule (extracted form green tea) on children from 6 to 12 years old with Intellectual Development Disorder (Down syndrome and Fragile X syndrome).
The secondary objective is to evaluate the benefits of the EGCG on attention, memory, executive functions, language and adaptive behaviour of these children. Dyrk1A and homocysteine in plasma will also be quantified, using them as biomarkers of efficacy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
Time frame: From day -5 to day 252 (through study completion)
Medical evaluations of incidence, nature, severity and causality of Adverse Events and Serious Adverse Events (SAE).
Time frame: Days -5, 5, 42, 84, 126, and 168.
The finding of an elevated alanine transaminase (ALT) or aspartate transaminase (AST) (>3xULN), elevated total bilirubin (>2xULN)
Time frame: Days -5, 42, 84, 126, and 168.
Elevated TSH (>10 microU/mL) or any decrease of free T4 below the lower limit of normal values (<0.8 ng/dL)
Time frame: Days -15, 84, and 168
Serum creatinine will be measured at various time points and an increase exceeding x1.5 ULN (upper limit of normal values) that is confirmed by a repeat testing within 3 days.
Time frame: Days -15, 84, and 168
Electroencephalogram recording to detect epileptiform abnormalities and/or seizure activity and/or pro-convulsive effects in pediatric participants, enabling a deeper understanding of the pharmacological effects of the intervention.
Time frame: Days -56 and 168
A QTcF (Fridericia's correction) value (mean of the three measurements) exceeding 500 ms when confirmed in repeat measurement within 15-30 minutes will be recorded as SAE.
A QTcF value exceeding a change from screening (mean of three time-matched measurements) of 60 ms when confirmed in repeat measurement within 15-30 minutes will be recorded as SAE.
Time frame: Days -56 and 168
Doppler echocardiogram is used to look at how blood flows through the heart chambers, heart valves, and blood vessels. The movement of the blood reflects sound waves to a transducer. The ultrasound computer then measures the direction and speed of the blood flowing through heart and blood vessels.
Time frame: Days -56 and 168
This measure is known as an ejection fraction or EF.
Time frame: Days -15, 168 and 252
Assessed by Picture Naming (PN) (WPPSI-IV). It is a verbal Comprehension subtest. It has 24 items. The child should name the drawings shown in the stimulus book. PN measures expressive language, ability and language development. Range score 0-24. Higher score is better outcome.
Time frame: Days -1,168 and 252
Assessed by Receptive Vocabulary (RV)(WPPSI-IV). It is a verbal comprehension subtest. It has 31 items. The child selects the picture that best represents the word the examiner reads aloud. RV measures receptive language ability and language development. Range score 0-40. Higher score is better outcome.
Time frame: Days -1,168 and 252
Assessed by Sentence Repetition (NEPSY-II): This subtest is designed to assess the ability to repeat sentences of increasing complexity and length. The child is read a series of sentences and asked to recall each sentence immediately after it is presented. Range score 0-34. Higher score is better outcome.
Time frame: Days -1,168 and 252
Assessed by Picture memory (WPPSI-IV). This subtest measures visual WM. It has 35 items. The child views a stimulus page of pictures for a specified time and then selects these pictures from options on a response page, for which a set of stimuli is viewed and then recognized from among a set of responses. Range score 0-35. Higher score is better outcome.
Time frame: Days -1,168 and 252
Subjects are asked to generate as many words as possible in 1 minute belonging to the category of "animals". No range score. A higher score is better outcome.
Time frame: Days -1,168 and 252
Assessed by Cats & Dogs Test. 16 pictures presented on a single strip of card (two trials with two conditions, control and experimental-inhibition). Measures of task accuracy in the experimental inhibition trial (total number of correct responses, range score 0-16) and total time performance (in seconds) were included in the analyses.
Time frame: Days -1,84,168 and 252
Assessed by Dimensional Change Card Sort (DCCS). Sort a series of bivalent test cards, according to one dimension(colour) or another(shape). Range score 0-24, higher score is better outcome.
Time frame: Days -1,168 and 252
Assessed by Blocks Design(WPPSI-IV). It is a visual spatial subtest which has 17 items. It measures ability to analyze and synthesize abstract visual stimuli. Range score 0-34, higher score is better outcome.
Time frame: Days -1,168 and 252
Changes in adaptive behavior
For all measures: a higher score is a better outcome
Time frame: Baseline, months 3 and 6
Dyrk1A and homocysteine (markers of efficacy); and Catechins and EGC concentrations (EGCG metabolites).
Time frame: Months -1, 3 and 6
Exploratory biomarkers: determination of folate in blood samples
Time frame: Months -1, 3 and 6
In the PERSEUS project spot urine samples will be collected to further evaluate the metabolome of subjects with Down syndrome, seeking biomarkers of treatment efficacy or those differentiating responders and non-responders. Analysis will be focused in the biosynthesis and metabolism of neurotransmitters, the kynurenine pathway and the hypothalamic-hypophyseal-adrenal axis.
Time frame: Baseline, months 6 and 9
Evaluating changes in executive performance. BRIEF-P is a widely used caregiver questionnaire of everyday skills reflective of abilities in the executive domain. It generates a range of scales, including scales specific to working memory and inhibitory control.Raw scores and T-scores will be derived for the following scales: inhibit, shift, emotional control, initiate, working memory, plan/organize, organization of materials and monitor.
Time frame: Baseline, months 6 and 9
Evaluating changes in memory performance. OMQ-PF is a 27-item questionnaire designed to ascertain parental perceptions about their child's memory function. All items are rated on a 5-point Likert (from 1- Strongly agree to 5-Strongly disagree OR 1- Never to 5- Always).
Time frame: Baseline, months 6 and 9
Evaluating Quality of life.
The PedsQL measurement model was designed to integrate the merits of generic and disease-specific instruments to evaluate quality of life. Three modules will be used:
Time frame: Baseline, months 6 and 9
Rebound effects after discontinuation of treatment measures: evaluating changes sleep disturbances.
CSHQ is a 22-item parent-report questionnaire that encompasses eight domains:
Time frame: Baseline, months 6 and 9
Rebound effects after discontinuation of treatment measures: evaluating changes in disrupting behaviors.
The ABC-C is a 58-item rating scale used to assess maladaptive behaviors across five original dimensions or subscales (Items are evaluated on a four-point Liker scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree)).
Time frame: Baseline, months 6 and 9
KIDMED index includes 16 questions based on the principles of the Mediterranean diet, where higher scores indicate greater adherence to healthy diet. Range score -4 -16.
Time frame: Baseline, months 6 and 9
This variable will be created by computing the sum of the Z-scores from tests that make up IDD-CHILD battery described in secondary outcome measures. No range score. A higher score is better outcome.
Parc de Salut Mar
Other
Acronym: PERSEUS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06740162
Abnormalities, Multiple, Aniridia
Fayetteville, Arkansas, United States
View Trial DetailsNCT05301361
Abnormalities, Multiple, Attention Deficit Disorder with Hyperactivity
Sacramento, California, United States
View Trial DetailsNCT03836300
22q11 Deletion Syndrome, Abnormalities, Multiple
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT06592404
Abnormalities, Multiple, Autism Spectrum Disorder
Sittard, Limburg, Netherlands
View Trial Details